¨
MOZZICONACCI AND SCHONEICH
16
5. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M.
2011. Oxytocin and vasopressin in the human brain: Social
neuropeptides for translational medicine. Nat Rev Neurosci
12(9):524–538.
6. Chaibva FA, Walker RB. 2007. Development and validation of
a stability-indicating analytical method for the quantitation
of oxytocin in pharmaceutical dosage forms. J Pharm Biomed
Anal 43(1):179–185.
7. Karbiwnyk CM, Faul KC, Turnipseed SB, Andersen WC,
Miller KE. 2008. Determination of oxytocin in a dilute IV so-
lution by LC-MS(n). J Pharm Biomed Anal 48(3):672–677.
8. Mueller JM, Pierce JG, Davoll H, Duvigneaud V. 1951.
The oxidation of oxytocin with performic acid. J Biol Chem
191(1):309–313.
18. Mozziconacci O, Haywood J, Gorman EM, Munson E,
Scho¨neich C. 2012. Photolysis of recombinant human insulin
in the solid state: Formation of a dithiohemiacetal prod-
uct at the C-terminal disulfide bond. Pharm Res 29(1):121–
133.
19. Mozziconacci O, Kerwin BA, Scho¨neich C. 2010. The exposure
of a monoclonal antibody, IgG1, to UV-light leads to protein
dithiohemiacetal and thioether cross-links. Chem Res Toxicol
23(8):1310–1312.
20. Lepre AM, Sutherland JC, Trunk JG, Sutherland BM. 1998. A
robust, inexpensive filter for blocking UVC radiation in broad-
spectrum ‘UVB’ lamps. J Photochem Photobiol B 43(1):34–40.
21. Ikehata K, Duzhak TG, Galeva NA, Ji T, Koen YM, Hanzlik
RP. 2008. Protein targets of reactive metabolites of thiobenza-
mide in rat liver in vivo. Chem Res Toxicol 21(7):1432–1442.
22. Pharmeuropa. 1990. The European Pharmacopoeia Forum.
Strasbourg: Council of Europe, pp 38–45.
23. Wysocki VH, Tsaprailis G, Smith LL, Breci LA. 2000. Mobile
and localized protons: A framework for understanding peptide
dissociation. J Mass Spectrom 35(12):1399–1406.
24. Thompson SD, Carroll DG, Watson F, O’ Donnell M, McG-
lynn SP. 1966. Electronic spectra and structure of sulfur com-
pounds. J Chem Phys 45(5):1367–1379.
25. Autrey T, Devadoss C, Sauerwein B, Franz JA, Schuster GB.
1995. Solvent cage recombination of 4-benzoylphenylthiyl rad-
icals: Fast intersystem crossing of triplet sulfur-centered rad-
ical pairs. J Phys Chem 99(3):869–871.
26. Mozziconacci O, Sharov V, Williams TD, Kerwin BA,
Scho¨neich C. 2008. Peptide cysteine thiyl radicals abstract
hydrogen atoms from surrounding amino acids: The photol-
ysis of a cystine containing model peptide. J Phys Chem B
112(30):9250–9257.
27. Fung YM, Kjeldsen F, Silivra OA, Chan TW, Zubarev RA.
2005. Facile disulfide bond cleavage in gaseous peptide and
protein cations by ultraviolet photodissociation at 157 nm.
Angew Chem Int Ed Engl 44(39):6399–6403.
28. Hug GL, Janeba-Bartoszewicz E, Filipiak P, Pedzinski T,
Kozubek H, Marciniak B. 2008. Evidence for heterolytic cleav-
age of C-S bonds in the photolysis of 1,3,5-trithianes. Polish J
Chem 82:883–892.
29. Janeba-Bartoszewicz E, Hug GL, Andrzejewska E, Marciniak
B. 2006. Photochemistry of 1,3,5-trithianes in solution: Steady-
state and laser flash photolysis studies. J Photochem Photobiol
A 177(1):17–23.
30. Burdzinski G, Marciniak B. 2008. Photoinduced ultrafast ring-
opening reaction in trithianes in solution. Chem Phys Lett
465(1–3):45–47.
9. Turner RA, Pierce JG, Duvigneaud V. 1951. The desulfuriza-
tion of oxytocin. J Biol Chem 193(1):359–361.
10. Groot ANJA, Vree TB, Hogerzeil HV, Walker GJA. 1997. Sta-
bility of oral oxytocics in tropical climates: Results of simu-
lation studies on oral ergometrine, oral methylergometrine,
buccal oxytocin and buccal desamino-oxytocin. Geneva,
Switzerland: World Health Organization.
11. Hawe A, Poole R, Romeijn S, Kasper P, Heijden R, Jiskoot
W. 2009. Towards heat-stable oxytocin formulations: Analy-
sis of degradation kinetics and identification of degradation
products. Pharm Res 26(7):1679–1688.
12. Avanti C, Amorij J-P, Setyaningsih D, Hawe A, Jiskoot W,
Visser J, Kedrov A, Driessen AJM, Hinrichs WLJ, Frijlink HW.
2011. A new strategy to stabilize oxytocin in aqueous solutions:
I. The effects of divalent metal ions and citrate buffer. AAPS
J 13(2):284–290.
13. Poole RA, Kasper PT, Jiskoot W. 2011. Formation of amide-
and imide-linked degradation products between the peptide
drug oxytocin and citrate in citrate-buffered formulations. J
Pharm Sci 100(7):3018–3022.
14. Hogerzeil HV, Walker GJA, de Goeje MJ. 1993. Stability of
injectable oxytocics in tropical climates. Action Programme on
Essential Drugs. Geneva, Switzerland: World Health Organi-
zation, pp 1–50.
15. Cesarini JP, Court L, McKinlay A, Sliney D, Selgrade MJ,
Johnson G, Armstrong B, Van Loveren H, Koppikar A, Tyrrell
RM, van der Leun JC, Badr IA, Kulandaivelu G. 1994. Envi-
ronmental Health Criteria (EHC) 160: Ultraviolet radiation.
Geneva, Switzerland: World Health Organization.
16. Barro´n LB, Waterman KC, Filipiak P, Hug GL, Nauser
T, Scho¨neich C. 2004. Mechanism and kinetics of photoi-
somerization of a cyclic disulfide, trans-4,5-dihydroxy-1,2-
dithiacyclohexane. J Phys Chem A 108(12):2247–2255.
17. Mozziconacci O, Kerwin B, Scho¨neich C. 2010. Photolysis of
an intrachain peptide disulfide bond: Primary and secondary
processes, formation of H2S, and hydrogen transfer reactions.
J Phys Chem B 114(10):3668–3688.
31. Asmus KD, Hug GL, Bobrowski K, Mulazzani QG, Marciniak
B. 2006. Transients in the oxidative and H-atom-induced
degradation of 1,3,5-trithiane. Time-resolved studies in aque-
ous solution. J Phys Chem A 110(29):9292–9300.
JOURNAL OF PHARMACEUTICAL SCIENCES
DOI 10.1002/jps